Trial Profile

A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects With Hypothalamic Obesity

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2026 According to a Rhythm Pharmaceuticals media release, results form this trial were presented at the Endocrine Society's Annual Meeting (ENDO 2026) in Chicago.
16 Jun 2026 Results presented in a Rhythm Health Media Release.
18 Nov 2024 According to a Rhythm media release, A cross-sectional analysis of 50 patients aged 2 to 17 years, with rare MC4R pathway diseases who participated in one of five different clinical trials of setmelanotide, including this one, was presented at European Society for Paediatric Endocrinology (ESPE 2024), held Nov 16-18, 2024, at Liverpool, UK.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com